GNTA vs. ALGS, IKNA, TSBX, ENTX, CDTX, CRTX, TIL, ELUT, JATT, and DYAI
Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Aligos Therapeutics (ALGS), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Entera Bio (ENTX), Cidara Therapeutics (CDTX), Cortexyme (CRTX), Instil Bio (TIL), Elutia (ELUT), JATT Acquisition (JATT), and Dyadic International (DYAI). These companies are all part of the "medical" sector.
Aligos Therapeutics (NASDAQ:ALGS) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.
60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 16.5% of Aligos Therapeutics shares are held by insiders. Comparatively, 29.0% of Genenta Science shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Aligos Therapeutics received 18 more outperform votes than Genenta Science when rated by MarketBeat users. However, 83.33% of users gave Genenta Science an outperform vote while only 62.16% of users gave Aligos Therapeutics an outperform vote.
Genenta Science has lower revenue, but higher earnings than Aligos Therapeutics.
Genenta Science has a net margin of 0.00% compared to Genenta Science's net margin of -607.03%. Aligos Therapeutics' return on equity of 0.00% beat Genenta Science's return on equity.
In the previous week, Genenta Science's average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.
Aligos Therapeutics has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.
Summary
Genenta Science beats Aligos Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Genenta Science News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genenta Science Competitors List
Related Companies and Tools
